Back to search

Article

Non-Invasive Molecular Testing for Osimertinib Acquired Resistance in T790M Positive Advanced Non-Small Cell Lung Cancer

2025-11-17

Abstract excerpt

<title>Abstract</title> <p> Introduction: Data concerning the acquired resistance mechanisms to osimertinib in epidermal growth factor receptor (EGFR <italic>) T790M</italic> -positive advanced non-small cell lung cancer (NSCLC) are limited, pwithin the Asian population. This study utilized Non-invasive Molecular Testing (NIMT) to characterize these resistance mechanisms and evaluate their clinical impact. Met...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
471ee127-c4bd-5c83-ac24-a3c66db7d9c6
DOI
10.21203/rs.3.rs-7683102/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Non-Invasive Molecular Testing for Osimertinib Acquired Resistance in T790M Positive Advanced Non-Small Cell Lung CancerDOI 10.21203/rs.3.rs-7683102/v1
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.Semantic proximity
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.Semantic proximity
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to OsimertinibSemantic proximity
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.Semantic proximity
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.Semantic proximity
The allele frequency of EGFR T790M in ctDNA predicted clinical outcomes of Osimertinib in non-small cell lung cancer patients from a real-world studySemantic proximity
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.Semantic proximity
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial.Semantic proximity
Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib.Semantic proximity
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.Semantic proximity
Therapeutic approaches for T790M mutation positive non-small-cell lung cancer.Semantic proximity
EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcomeSemantic proximity
Select a neighboring publication to make it the new centre.